Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents.
Pharmacogenomics
; 18(13): 1225-1239, 2017 08.
Article
em En
| MEDLINE
| ID: mdl-28745576
ABSTRACT
BACKGROUND:
Patients undergoing elective percutaneous coronary intervention (PCI) with drug-eluting stents (DES) who have impaired clopidogrel response, have a higher risk of subsequent major adverse cardiovascular events (MACE). AIM OF THE STUDY To establish the relationship between CYP2C19 genotype, clopidogrel responsiveness and 1-year MACE. MATERIALS &METHODS:
Aspirin/clopidogrel responses were assessed with Multiplate Analyzer and CYP2C19*2 allele by SpartanRx.RESULTS:
A total of 42.0% carried ≥1 CYP2C19*2 allele. Prevalences of aspirin and clopidogrel high on-treatment platelet reactivity (HPR; local cutoffs 300 AU*min for aspirin and 600 AU*min for clopidogrel) were 11.5% and 19.8% respectively. In multivariate ana-lysis, clopidogrel HPR was found to be an independent predictor for 1-year MACE (adj HR 3.48, p = 0.022 ).CONCLUSION:
Having clopidogrel HPR could be a potentially modifiable risk factor guided by phenotyping.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polimorfismo Genético
/
Ticlopidina
/
Inibidores da Agregação Plaquetária
/
Doenças Cardiovasculares
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Citocromo P-450 CYP2C19
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Pharmacogenomics
Ano de publicação:
2017
Tipo de documento:
Article